Goldman Sachs Maintains Neutral on HUTCHMED (China), Lowers Price Target to $14

Benzinga Newsdesk www.benzinga.com Negative 81.5%

Neg 81.5% Neu 0% Pos 0%

Goldman Sachs analyst Paul Choi maintains HUTCHMED (China) (NASDAQ:HCM) with a Neutral and lowers the price target from $16 to $14.